CGEN Compugen Ltd.

+0.02  (+1%)
Previous Close 3.39
Open 3.45
Price To Book 5.5
Market Cap 204266407
Shares 59,902,172
Volume 44,987
Short Ratio
Av. Daily Volume 192,499

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 trial initiated September 2018.
Solid tumors
Phase 1 trial initiated September 2018.
BAY 1905254
Solid tumors

Latest News

  1. What Makes Compugen (CGEN) a New Strong Buy Stock
  2. Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting
  3. Chinese Regulatory Authority Approves IND Application of Oramed's Oral Insulin Capsules
  4. Compugen Announces Purchase of Company Shares by its Board of Directors and Members of Management
  5. Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate
  6. Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4
  7. Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?
  8. Compugen to Present at the Cowen and Company 39th Annual Health Care Conference
  9. Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-Oncology Symposium
  10. Compugen Reports Fourth Quarter and Full Year 2018 Results and Announces Corporate Restructuring to Streamline Operations
  11. Compugen Fourth Quarter and Full Year 2018 Conference Call Scheduled for Tuesday, February 26, 2019 at 8:30 AM ET
  12. Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy
  13. How Much Of Compugen Ltd. (NASDAQ:CGEN) Do Institutions Own?
  14. Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium
  15. New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Biotherapeutics, ElectraMeccanica Vehicles, Compugen, and China HGS Real Estate — Consolidated Revenues, Company Growth, and Expectations for 2018
  16. Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy
  17. Compugen (CGEN) Reports Q3 Loss
  18. Compugen: 3Q Earnings Snapshot
  19. Compugen Reports Third Quarter 2018 Results
  20. Compugen Ltd. (CGEN) Sees Hammer Chart Pattern: Time to Buy?